Piramal adds antibody CDMO capabilities with investment in Yapan Bio

Transaction adds new technologies and capabilities in large molecules, including vaccines and gene therapy, to its global offering

Yapan Bio provides process development, scale-up, and cGMP compliant manufacturing of vaccines and biologics/bio-therapeutics, including high containment product classes (up to BSL-2+), recombinant vaccines, RNA/DNA vaccines, gene therapies, monoclonal antibodies, therapeutic proteins, and other complex biologics.

Investing in the company is regarded by Piramal as a shrewd move given the speed at which the biologics segment of the pharmaceutical industry is growing.

"During the past decade, biologics and their accompanying development services are the fastest growing segments of the CDMO market," said Peter DeYoung, CEO, Pharma Solutions, Piramal Pharma Limited.

Already, Yapan Bio has earned revenues of INR 11.8 cr ($1.56 million) for H1FY22 and is poised for fast growth in response to strong market demand.

Piramal Pharms Solutions currently offers integrated payload, conjugation and fill/finish services. The biologics capabilities of Yapan Bio can be synergistic with Piramal Pharms Solutions' antibody drug conjugation capabilities, particularly for customers who prefer the speed and simplicity of an integrated programme that involves development, manufacturing, conjugation, and fill/finish.